Sl. Wong et al., PHARMACOKINETICS OF SERTINDOLE AND DEHYDROSERTINDOLE IN VOLUNTEERS WITH NORMAL OR IMPAIRED RENAL-FUNCTION, European Journal of Clinical Pharmacology, 52(3), 1997, pp. 223-227
Objective: To study the effect of renal impairment on the pharmacokine
tics of sertindole. Methods: A single 4 mg oral dose of sertindole was
given to normal subjects (n = 6) and subjects with various degrees of
impaired renal function (n = 18) classified into mild, moderate, and
severe/hemodialysis based on their creatinine clearance). The relation
ships between the pharmacokinetic parameters and the degree of renal i
mpairment were investigated using regression analysis with creatinine
clearance as an explanatory variable along with body weight. Subjects
were also genotyped for CYP2DG-A or 2D6-B mutations. Results: The mean
CL/f and t(1/2) values of sertindole ranged from 14 to 31 l.h(-1) and
from 73 to 93 h, respectively, and were not significantly related to
creatinine clearances. There was no indication of any influence of cre
atinine clearance on the fraction of sertindole (0.994-0.995) binding
to plasma proteins. The total fraction of the sertindole dose removed
by dialysis was less than 0.1%. Subjects with B/B genotype (n = 2) for
CYP2D6 were associated with a distinctly lower clearance of sertindol
e (6.3 vs 25.3 1.h(-1)) than subjects with wt/wt genotype for CYP2D6.
Conclusions: Since the pharmacokinetics of sertindole are unchanged by
renal impairment, dosage adjustment does not appear to be necessary f
or subjects with various degrees of renal insufficiency or subjects wi
th renal failure requiring hemodialysis.